Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $380,330.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 7,300 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $52.10, for a total transaction of $380,330.00. Following the completion of the transaction, the executive vice president now directly owns 118,920 shares of the company’s stock, valued at approximately $6,195,732. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, September 3rd, Fady Ibraham Malik sold 7,384 shares of Cytokinetics stock. The stock was sold at an average price of $57.01, for a total value of $420,961.84.
• On Tuesday, August 6th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $53.71, for a total transaction of $392,083.00.
• On Tuesday, July 23rd, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $57.02, for a total value of $416,246.00.
• On Tuesday, July 9th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $55.90, for a total value of $408,070.00.

Cytokinetics Stock Down 0.4 %

Shares of NASDAQ CYTK traded down $0.20 during mid-day trading on Tuesday, reaching $52.60. 990,817 shares of the company’s stock traded hands, compared to its average volume of 2,227,588. The company has a debt-to-equity ratio of 5.93, a current ratio of 10.39 and a quick ratio of 10.39. The stock has a market cap of $5.52 billion, a P/E ratio of -9.78 and a beta of 0.77. Cytokinetics, Incorporated has a 1-year low of $25.98 and a 1-year high of $110.25. The business has a 50-day simple moving average of $55.71 and a 200 day simple moving average of $58.67.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.25). The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $7.61 million. During the same period in the prior year, the firm posted ($1.34) EPS. Cytokinetics’s revenue for the quarter was down 71.3% on a year-over-year basis. On average, analysts expect that Cytokinetics, Incorporated will post -5.15 EPS for the current fiscal year.

Institutional Trading of Cytokinetics

Hedge funds have recently added to or reduced their stakes in the business. J.Safra Asset Management Corp grew its stake in shares of Cytokinetics by 642.3% in the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 456 shares during the last quarter. EntryPoint Capital LLC bought a new stake in shares of Cytokinetics in the 1st quarter valued at about $74,000. Bessemer Group Inc. increased its position in shares of Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 1,255 shares in the last quarter. Quarry LP increased its stake in shares of Cytokinetics by 233.3% in the second quarter. Quarry LP now owns 2,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,400 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Cytokinetics during the 2nd quarter valued at about $190,000.

Wall Street Analyst Weigh In

CYTK has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a research report on Thursday, September 5th. JMP Securities reiterated a “market outperform” rating and issued a $78.00 target price on shares of Cytokinetics in a report on Wednesday, September 4th. The Goldman Sachs Group downgraded shares of Cytokinetics from a “buy” rating to a “neutral” rating and lowered their target price for the company from $85.00 to $60.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Cytokinetics in a report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Cytokinetics in a report on Monday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.67.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.